Dr Saeed Dabestani speaks to ecancer about urine glycosaminoglycan scores for surveillance of recurrence in Intermediate and high-risk non-metastatic clear cell renal cell carcinoma.

The AURORAX-0087 study is an observational prospective multicenter diagnostic test cohort study

It introduces a urine-based diagnostic test that measures glycosaminoglycan to detect clear cell renal cancer recurrence.

Utilising mass spectrometry, the test calculates a GAGome score from urine samples of patients post-surgery.

With a sensitivity of 90% and a specificity of 51%, the test shows promise in reducing unnecessary scans and healthcare costs, although it has a limited follow-up period and is not yet market-approved.

To read the news story click here.